Rare diseases
Investigational molecules
Locations
Back to Germany407 clinical trials in Duesseldorf, Germany across 5 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.
Our site in GermanyKlinischeStudien.de(opens in a new tab)Long-term Study on Treatment Response in Chronic Hepatitis B Patients Using Bepirovirsen
GermanyStudy on the Effects of Gemlapodect for Adults and Adolescents with Tourette Syndrome
GermanyStudy on the Effects of AMX0035 (Phenylbutyrate and Ursodoxicoltaurine) in Patients with Progressive Supranuclear Palsy
GermanyStudy on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy
GermanyStudy on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata
GermanyStudy on the Effectiveness and Safety of Litifilimab for Patients with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy
GermanyStudy of Emrusolmin for Treating Adults with Multiple System Atrophy
GermanyStudy on Adjuvant Therapy with Capecitabine for Stage II Colon and Rectal Cancer Patients with Positive ctDNA After Tumor Removal
GermanyStudy of Durvalumab, Tremelimumab, and Lenvatinib with TACE for Patients with Liver Cancer (Hepatocellular Carcinoma)
GermanyStudy on Reducing Lipoprotein Apheresis with Pelacarsen in Patients with High Lipoprotein(a) and Heart Disease in Germany
GermanyStudy of nivolumab, relatlimab and bevacizumab combination for patients with untreated advanced or metastatic liver cancer (hepatocellular carcinoma)
GermanyStudy of Niraparib and Dostarlimab for Children with Recurrent or Hard-to-Treat Solid Tumors
GermanyThe busiest research cities in the country
What the registry says about research in the country
In Düsseldorf, a large share of trials focuses on cancer research and blood cancers, with studies in breast cancer, colorectal cancer, prostate cancer, multiple myeloma, and leukemia. These trials are mainly testing new treatment combinations, improving post-surgery care, and exploring ways to delay or prevent recurrence.
This field is especially active across the city’s research sites, reflecting a strong interest in both common and hard-to-treat malignancies.
Another important area is skin and connective tissue disease research, including studies on psoriasis, actinic keratosis, androgenetic alopecia, and facial line treatments. These trials are mainly aimed at evaluating new topical or injectable therapies and improving visible symptom control.
Several of these studies are designed to compare active treatment with control care and help refine everyday dermatologic treatment options.
Trials in digestive system diseases and virus diseases include research on chronic hepatitis D, metabolic dysfunction-associated steatotic liver disease, and advanced cancers involving the pancreas, colon, and bile ducts. The main goal is to improve treatment effectiveness and support better disease control in difficult liver and gastrointestinal conditions.
These studies highlight a strong focus on therapies for chronic liver illness and advanced abdominal cancers.
Research in nervous system diseases includes trials for multiple sclerosis and other neurological conditions, with an emphasis on long-term safety and treatment benefit. In Düsseldorf, these studies are helping assess whether newer immune-based approaches can better support patients over time.
This area reflects ongoing interest in therapies that may offer steadier disease control with acceptable tolerability.
Pediatric trials cover serious conditions such as high-risk neuroblastoma, acute lymphoblastic leukemia, and respiratory distress in preterm infants. These studies aim to improve survival, reduce complications, and support better long-term outcomes in children and young people.
These trials bring together cancer care and neonatal research, showing a wide pediatric research footprint in the city.
Several studies address hemic and lymphatic diseases, especially myelodysplastic syndromes, anemia, and refractory hematologic malignancies. The purpose is to find better ways to restore blood counts, improve transfusion independence, and treat patients whose disease has returned or no longer responds to standard therapy.
This research area is particularly important for patients with limited treatment options and persistent blood-related symptoms.
Düsseldorf also hosts trials in hormonal diseases and nutritional and metabolic diseases, including work on hair loss linked to hormonal imbalance and liver-related metabolic disorders. These studies are designed to test treatment effectiveness and improve symptom management in conditions that often affect quality of life.
These trials connect chronic metabolic care with visible, patient-centered outcomes.
The city’s trial portfolio includes immune system disease research and studies linked to virus diseases, especially where immune pathways affect chronic illness or cancer care. Researchers are exploring new treatment options that may improve control of persistent viral infection and immune-driven disease.
This work shows how immunology and virology often overlap in modern clinical research.
A smaller but important part of the research landscape involves diagnostic techniques and equipment, including studies that assess how well advanced imaging can identify disease and guide care. These trials are focused on improving diagnosis and helping clinicians distinguish between disease subtypes more accurately.
In Düsseldorf, diagnostic research complements the treatment studies by strengthening the tools used to identify and monitor disease.
Trials in respiratory tract diseases include research aimed at improving outcomes for preterm infants with breathing problems early in life. The focus is on prevention and better long-term lung function, with the goal of reducing complications that can affect childhood development.
This area links specialized newborn care with research designed to improve later respiratory health.
Some trials in Düsseldorf span advanced solid tumors and other difficult-to-treat conditions, reflecting a broad translational research effort. These studies are often designed to test whether new therapies can produce meaningful disease control in patients with limited standard options.
This part of the research landscape supports the development of new approaches across multiple cancer types.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
